Sign in
CADL Stock Price, Chart, Stats & News
Candel Therapeutics, Inc.
Save
Candel Therapeutics, Inc. (CADL) does not currently pay a dividend.
561.09M
Market cap
–
Current P/E
43.48x
Forward P/E
CADL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -30.50% |
ROE | -51.44% |
D/E | 0.04x |
Interest coverage ratio | -22.78x |
CADL valuation
P/E | – |
P/S | – |
P/B | 5.09x |
P/CF | -6.89x |
P/FCF | -6.79x |
P/OCF | -6.89x |
PEG | 0.23x |
EV multiple | -8.05x |
About
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma.
Similar securities
Based on sector and market capitalization
Report issue